Elex biotech designs and develops novel drugs to treat heart failure and ventricular arrhythmias, and is a Portland State University Business Accelerator company-in-residence. Often associated with aging, heart failure is the inability of the heart to maintain cardiac output sufficient to meet the body’s needs; ventricular arrhythmia is an abnormal heart rate that, if left unchecked, can lead to death, especially in people over 65. With heart failure and arrhythmias claiming more than 300,000 lives a year at a cost of roughly $34.4 million, the need for new treatments is imperative. Elex Biotech’s mission is to fill that need.
Drug therapies currently in use to treat heart failure and ventricular arrhythmias are not effective. Elex Biotech draws on proprietary compounds and methods developed at Portland State University by Drs. Jonathan Abramson and Robert Strongin, and licensed to Elex Biotech by the office of Innovation & Intellectual Property. Using Small Business and grant funding awarded by the National Institutes of Health, Elex Biotech is testing drugs with the potential to be exponentially more potent than those one the market today, treatment that in the future may save thousands of lives and millions of dollars worldwide.
Elex Biotech was cofounded by Portland State University professors Abramson and Strongin and CEO Dr. Sandra Shotwell, who brings to the team extensive experience in commercializing innovation technologies.